Lizolid 300ml IV Injection contains Linezolid 600mg, a synthetic antibiotic belonging to the oxazolidinone class, indicated for the treatment of serious Gram-positive bacterial infections. It is primarily used in hospital settings for infections caused by multi-resistant strains, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae. The intravenous formulation allows for rapid systemic distribution, making it suitable for severe infections such as pneumonia, complicated skin and soft tissue infections, and bacteremia. Linezolid exerts its antibacterial effect by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex. Lizolid 300ml IV Injection should be administered under strict medical supervision with dosage adjustments based on infection severity and patient renal and hepatic function. Common adverse effects include gastrointestinal disturbances, headache, and potential hematological toxicity such as thrombocytopenia, especially with prolonged use. Monitoring of complete blood counts and neurological status is recommended during therapy. This product is contraindicated in patients with known hypersensitivity to Linezolid or other oxazolidinones and should be used cautiously in patients receiving serotonergic agents due to the risk of serotonin syndrome.